Φορτώνει......
Phase II Studies of Two Different Schedules of Dasatinib in Bone-Metastasis Predominant Metastatic Breast Cancer: SWOG S0622
PURPOSE: Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple oncogenic tyrosine kinases, suggested efficacy in tumor control and palliation of bone metastases in metastatic breast cancer (MBC). This...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Breast Cancer Res Treat |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5021222/ https://ncbi.nlm.nih.gov/pubmed/27475087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3911-z |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|